Wound healing compositions and treatments
AssigneeCoDa Therapeutics, Inc.
InventorsAnthony Phillips, David Eisenbud, Scott Bannan, David Pool, Grove Matsuoka, Tracey Sunderland, Bradford Duft
Life of this patent
Estimating the term…
Abstract
This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
Claims64
A method of treating a refractory wound, comprising:
- a. measuring the size a skin wound upon initial presentation for treatment to obtain a first size measurement;
- b. administering compression bandaging to the wound;
- c. measuring the size of the wound after 2-4 weeks of administering the compression to obtain a second size measurement;
- d. determining that the second size indicator of the wound is within a predetermined range from about −30 to about +35% of the first size measurement, thereby identifying a refractory wound;
- and
- e. administering to the refractory wound a pharmaceutical composition comprising a pharmaceutical carrier suitable for topical administration of an anti-connexin polynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43.
A method of treating a refractory venous leg ulcer, comprising administering to the ulcer a pharmaceutical carrier suitable for topical administration and about 3-30 mg/mL of an anti-connexin polynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43.
An article of manufacture for use in treating a refractory wound, comprising a receptacle containing a composition comprising a pharmaceutical carrier suitable for topical administration having about 20-23% of a nonionic polyoxyethylene-polyoxypropylene and about 3-30 mg/mL of a anti-connexin oligodeoxynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43, and, and instructions for the treatment of the refractory wound, by topically administering the composition to or in the proximity of the wound.
A method of detecting a refractory wound with an increased likelihood of complete closure following topical administration to the recalcitrant wound of a composition comprising a pharmaceutical carrier suitable for topical administration of an anti-connexin oligodeoxynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43, the method comprising:
- a. measuring the size of a skin wound upon initial presentation for treatment, to obtain a first size measurement;
- b. administering compression bandaging to the wound;
- c. measuring the size of the skin wound after about 2-4 weeks of administering the standard of care, to obtain a second size measurement;
- d. detecting that the second size measurement is within −30% to +35% of the first size measurement, thereby detecting a refractory wound having an increased likelihood of complete closure following topical administration to the recalcitrant wound of a pharmaceutical composition comprising a pharmaceutical carrier suitable for topical administration having about 20-23% of a nonionic polyoxyethylene-polyoxypropylene and about 3-30 mg/mL of an anti-connexin oligodeoxynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43;
- and
- e. administering the pharmaceutical composition to the wound.
The method according to one of claim 13 or 30 according to claim 67 or 85, wherein said gel is a pluronic F-127.
A method of treating a subject having a wound not healing at an expected rate, comprising administering to the wound a composition comprising an anti-connexin 43 polynucleotide and a pharmaceutically acceptable carrier, wherein the amount of said anti-connexin 43 polynucleotide administered to said wound ranges from about 30 to about 500 μg per square centimeter of said wound, the improvement comprising determining whether the wound heals by more than about 30-35% during a 2-4 week run-in period during which the wound is treated by compression and, if not, applying said anti-connexin 43 composition to said wound.
A program of instructions tangibly embodied on a non-transitory computer-readable medium for execution by a computer to perform a wound measuring process in a handheld laser device for measuring a size indicator of a wound, the computer having a processor configured to determine whether a chronic wound has an increased likelihood of complete closure, the program providing:
- a. receipt, on the computer, of measurements of a size indicator of the wound before a first treatment is administered;
- b. receipt, on the computer, of measurements of the size indicator of the wound after a 2-4 week run-in period;
- c. comparing the size indicator measurements from steps a) and b) and detecting that the area of the wound is within −15% to +30% of its area prior to administering the first treatment, thereby determining an increased likelihood of complete closure following topical administration to the recalcitrant wound of a composition comprising from about 20-23% of a nonionic polyoxyethylene-polyoxypropylene copolymer and a single-stranded anti-connexin 43 antisense oligodeoxynucleotide present at a concentration from 3.0 to about 30.0 milligrams per milliliter.
Dependencies are inferred from the claim text.